WO2005010153A3 - Anticorps et utilisations de ceux-ci - Google Patents

Anticorps et utilisations de ceux-ci Download PDF

Info

Publication number
WO2005010153A3
WO2005010153A3 PCT/US2004/021002 US2004021002W WO2005010153A3 WO 2005010153 A3 WO2005010153 A3 WO 2005010153A3 US 2004021002 W US2004021002 W US 2004021002W WO 2005010153 A3 WO2005010153 A3 WO 2005010153A3
Authority
WO
WIPO (PCT)
Prior art keywords
metastasis
library
present
fragments
compositions
Prior art date
Application number
PCT/US2004/021002
Other languages
English (en)
Other versions
WO2005010153A2 (fr
Inventor
Daniel Plaksin
Avigdor Levanon
Esther Szanton
Yocheved Hagay
Rachel Ben-Levy
Yael Nisgav
Tali Szrajber
Yariv Kanfi
Original Assignee
Bio Technology General Israel
Daniel Plaksin
Avigdor Levanon
Esther Szanton
Yocheved Hagay
Rachel Ben-Levy
Yael Nisgav
Tali Szrajber
Yariv Kanfi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Israel, Daniel Plaksin, Avigdor Levanon, Esther Szanton, Yocheved Hagay, Rachel Ben-Levy, Yael Nisgav, Tali Szrajber, Yariv Kanfi filed Critical Bio Technology General Israel
Priority to JP2006518730A priority Critical patent/JP2007528711A/ja
Priority to AU2004259406A priority patent/AU2004259406A1/en
Priority to EP04777308A priority patent/EP1649001A2/fr
Priority to BRPI0411945-2A priority patent/BRPI0411945A/pt
Priority to CA002536644A priority patent/CA2536644A1/fr
Priority to MXPA06000252A priority patent/MXPA06000252A/es
Publication of WO2005010153A2 publication Critical patent/WO2005010153A2/fr
Priority to IL172510A priority patent/IL172510A0/en
Publication of WO2005010153A3 publication Critical patent/WO2005010153A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps ou des fragments de ceux-ci se liant à des cellules cancéreuses et jouant un rôle important dans les phénomènes physiologiques, tels que le roulement de cellules et la métastase. L'invention concerne également des procédés thérapeutiques et diagnostiques, ainsi que des compositions utilisant de tels fragments d'anticorps. Les procédés et compositions selon l'invention peuvent être utilisés dans le ciblage d'agents thérapeutiques et dans le diagnostic, le pronostic et l'évaluation du stade de maladies et la thérapie destinée à celles-ci, telles que le cancer, notamment la croissance tumorale et la métastase, la leucémie, une maladie auto-immune et une maladie inflammatoire. L'invention concerne enfin une bibliothèque de domaines de liaison à l'immunoglobuline comprenant un domaine de liaison aux antigènes différent destiné à une liaison complémentaire, la bibliothèque présentant une diversité uniquement dans une chaîne lourde CDR3.
PCT/US2004/021002 2003-06-30 2004-06-30 Anticorps et utilisations de ceux-ci WO2005010153A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2006518730A JP2007528711A (ja) 2003-06-30 2004-06-30 抗体及びその使用
AU2004259406A AU2004259406A1 (en) 2003-06-30 2004-06-30 Antibodies and uses thereof
EP04777308A EP1649001A2 (fr) 2003-06-30 2004-06-30 Anticorps et utilisations de ceux-ci
BRPI0411945-2A BRPI0411945A (pt) 2003-06-30 2004-06-30 Anticorpos e seus usos
CA002536644A CA2536644A1 (fr) 2003-06-30 2004-06-30 Anticorps et utilisations de ceux-ci
MXPA06000252A MXPA06000252A (es) 2003-06-30 2004-06-30 Anticuerpos y usos de los mismos.
IL172510A IL172510A0 (en) 2003-06-30 2005-12-12 Antibodies and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61123803A 2003-06-30 2003-06-30
US10/611,238 2003-06-30

Publications (2)

Publication Number Publication Date
WO2005010153A2 WO2005010153A2 (fr) 2005-02-03
WO2005010153A3 true WO2005010153A3 (fr) 2008-03-13

Family

ID=34103137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/021002 WO2005010153A2 (fr) 2003-06-30 2004-06-30 Anticorps et utilisations de ceux-ci

Country Status (11)

Country Link
EP (1) EP1649001A2 (fr)
JP (1) JP2007528711A (fr)
KR (1) KR20060106631A (fr)
CN (1) CN101300021A (fr)
AU (1) AU2004259406A1 (fr)
BR (1) BRPI0411945A (fr)
CA (1) CA2536644A1 (fr)
IL (1) IL172510A0 (fr)
MX (1) MXPA06000252A (fr)
RU (1) RU2006102570A (fr)
WO (1) WO2005010153A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714978A1 (fr) * 2005-04-19 2006-10-25 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides servant au diagnostic et au traitement des tumeurs
WO2007067983A2 (fr) * 2005-12-09 2007-06-14 Wyeth Anticorps specifique de la sulfotyrosine et utilisation a cet effet
EP2161072A1 (fr) * 2008-09-03 2010-03-10 Gambro Lundia AB Membranes d'hémodialyse avec un seuil de coupure pour le traitement de patients nécessitant des hémodialyses régulières
EP2246364A1 (fr) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anticorps anti CXCR4 pour le traitement du VIH
EP2371863A1 (fr) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Anticorps humanisé anti CXCR4 pour le traitement du cancer
HUE041900T2 (hu) * 2012-01-20 2019-06-28 Genzyme Corp Anti-CXCR3 ellenanyagok
JP7240808B2 (ja) * 2014-07-08 2023-03-16 サンフォード バーナム プレビーズ メディカル ディスカバリー インスティテュート Ｐｓｇｌ－１モジュレーターおよびその使用
TWI753875B (zh) 2016-01-08 2022-02-01 美商美國全心醫藥生技股份有限公司 四價抗psgl-1抗體及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026667A1 (fr) * 1998-10-30 2000-05-11 Miller Jonathan L Regions variables de chaine lourde et de chaine legere d'anticorps diriges contre la glycoproteine plaquettaire humaine ib alpha
WO2002053700A2 (fr) * 2000-12-29 2002-07-11 Bio-Technology General Corp. Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026667A1 (fr) * 1998-10-30 2000-05-11 Miller Jonathan L Regions variables de chaine lourde et de chaine legere d'anticorps diriges contre la glycoproteine plaquettaire humaine ib alpha
WO2002053700A2 (fr) * 2000-12-29 2002-07-11 Bio-Technology General Corp. Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WARD ET AL.: "Mocarhagin, a Novel Cobra Venom Metalloproteinase, Cleaves the Platelet von Willebrand Factor Receptor Glycoprotein Iba. Identification of the Sulfated Tyrosine/Anionic Sequence Tyr-276-Glu-282 of Glycoprotein Iba as a Binding Site for von Willebrand.....", BIOCHEMISTRY, vol. 35, no. 15, 1996, pages 4929 - 4938 *

Also Published As

Publication number Publication date
WO2005010153A2 (fr) 2005-02-03
EP1649001A2 (fr) 2006-04-26
JP2007528711A (ja) 2007-10-18
BRPI0411945A (pt) 2006-10-24
AU2004259406A1 (en) 2005-02-03
IL172510A0 (en) 2006-04-10
KR20060106631A (ko) 2006-10-12
CN101300021A (zh) 2008-11-05
RU2006102570A (ru) 2007-08-20
CA2536644A1 (fr) 2005-02-03
MXPA06000252A (es) 2006-12-15

Similar Documents

Publication Publication Date Title
SG153825A1 (en) Multivalent immunoglobulin-based bioactive assemblies
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
JP2009518039A5 (fr)
JP2018538262A5 (fr)
WO2007067992A3 (fr) Anticorps monoclonaux humains se liant au fucosyl-gm1, et procedes d'utilisation de l'anti-fucosyl-gm1
UA99701C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1)
IL242336A (en) METHOD FOR IDENTIFICATING GLYCOTOPE CA6 AND USING A CYTOTOXIC BANGLE TO PREPARE A CANCER TREATMENT IN A CANCER DIAGNOSED PATIENT IN ACCORDANCE WITH THE METHOD
WO2009073533A3 (fr) Conjugués anticorps monoclonal-médicaments anti-b7h4 et procédés d'utilisation associés
WO2007073499A3 (fr) Molecules epha2 bite et leur utilisation
WO2008047242A3 (fr) Nouveaux anticorps anti-cd38 pour le traitement du cancer
CA2595610A1 (fr) Anticorps diriges contre l'angiopoietine 2 et leurs utilisations
EP3530736A3 (fr) Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
WO2010017500A3 (fr) Anticorps anti-cancer pancréatique
WO2005046573A3 (fr) Compositions d'anticorps pro104 et procedes d'utilisation associes
WO2009067660A3 (fr) Anticorps monoclonaux anti-facteur xi et procédés d'utilisation
WO2005058815A3 (fr) Anticorps ip-10 et leurs utilisations
WO2007016590A3 (fr) Compositions d'anticorps ovr232v3 et procedes d'utilisation
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
WO2005080431A3 (fr) Anticorps monoclonaux bloquant specifiquement l'activite biologique d'un antigene tumoral
WO2004101756A3 (fr) Compositions d'anticorps anti-ovr110, et leur procede d'utilisation
EA200800642A1 (ru) Специфичный к антигену са6 цитотоксический конъюгат и способы его применения
MX2007004247A (es) Agentes de aglutinacion especifica a angiopoyetina-2.
WO2006053110A3 (fr) Compositions d'anticorps anti-ovr110 et methodes d'utilisation correspondantes
WO2006116451A3 (fr) Anticorps a activite d'effecteur immunitaire et internalises dans des cellules positives vis-a-vis de l'endosialine
GEP20135826B (en) Novel antibodies used to treat cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480024914.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172510

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020057025517

Country of ref document: KR

Ref document number: 2536644

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006518730

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/000252

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 545005

Country of ref document: NZ

Ref document number: 2006102570

Country of ref document: RU

Ref document number: 200600862

Country of ref document: ZA

Ref document number: 2004777308

Country of ref document: EP

Ref document number: 2004259406

Country of ref document: AU

Ref document number: 485/DELNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004259406

Country of ref document: AU

Date of ref document: 20040630

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004777308

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 1020057025517

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0411945

Country of ref document: BR